Advertisement
ABBV vs AMGN
Which Stock Would AI Choose? AbbVie (ABBV) vs. Amgen (AMGN) Stock Comparison
Key Takeaways
- AbbVie (ABBV) has maintained steadier recent performance with positive Phase 3 results for its menstrual migraine treatment and completion of a major acquisition expanding its immunology pipeline.
- Amgen (AMGN) delivered strong Q2 2026 results and raised guidance but faced a sharp recent selloff linked to broader sector sentiment around cardiovascular pipeline risks.
- ABBV trades at a higher valuation with a larger market capitalization, while AMGN offers a lower forward price-to-earnings ratio amid its oncology and biosimilar growth drivers.
- Both companies benefit from robust immunology and oncology portfolios, yet ABBV shows more consistent month-to-date gains compared to AMGN’s recent volatility.
- Sector exposure remains similar in biotechnology, with ABBV emphasizing neuroscience expansion and AMGN highlighting lung cancer and cardiovascular programs.
- Market sentiment favors ABBV’s pipeline catalysts in recent weeks, while AMGN contends with spillover effects from competitor trial outcomes.
Introduction
Investors and traders often compare AbbVie (ABBV) and Amgen (AMGN) due to their positions as leading biotechnology companies with established product portfolios and active pipelines in immunology, oncology, and related therapeutic areas. This analysis examines their relative performance, business drivers, and market positioning in the current environment. The comparison appeals to those evaluating large-cap healthcare names for portfolio diversification, income generation through dividends, or exposure to innovation-driven growth. Both stocks have delivered solid year-to-date returns, yet recent developments highlight distinct trajectories that may influence allocation decisions.
ABBV Overview and Recent Performance
AbbVie operates as a global biopharmaceutical company focused on immunology, neuroscience, oncology, and aesthetics. In recent market activity, ABBV shares have shown resilience, advancing modestly amid broader sector movements. Positive topline Phase 3 LUNA trial results for atogepant in menstrual migraine treatment supported sentiment in early September. The company also completed its $10.9 billion acquisition of Apogee Therapeutics, bolstering its immunology capabilities with late-stage candidates. Q2 2026 revenues reached $16.99 billion, reflecting double-digit growth from key products such as Skyrizi and Rinvoq. Adjusted earnings guidance incorporated minor dilution from the acquisition while remaining within targeted ranges. Year-to-date performance stands near 15 percent, with one-month gains exceeding 3 percent as of mid-September.
AMGN Overview and Recent Performance
Amgen develops and commercializes therapies in oncology, cardiovascular disease, inflammation, and rare conditions. The company reported robust Q2 2026 results with revenues of $10.1 billion and raised full-year guidance. Pipeline progress includes positive Phase 3 data for IMDELLTRA in first-line small cell lung cancer maintenance. However, recent market activity featured notable pressure, with shares declining approximately 15 percent over five consecutive sessions following competitor trial setbacks in the Lp(a) cardiovascular space. Year-to-date returns remain positive near 18 percent, though one-month performance turned negative. Market capitalization stands around $204 billion, with the stock trading near $377 amid elevated volatility compared to earlier periods.
Trending AI Robots
Tickeron maintains a curated selection of AI trading bots designed for various market conditions. The platform offers hundreds of AI Trading Bots that trade thousands of different tickers across equities, with strategies spanning multiple timeframes, risk profiles, and performance metrics. Only those demonstrating strong suitability for prevailing conditions appear in the Trending AI Robots section. Available bots exhibit diverse statistics, including varying win rates, profit factors, and drawdown profiles, allowing users to review historical backtests and live signals. This resource provides traders with data-driven options tailored to individual preferences without requiring manual strategy development. Review the full collection on the Trending AI Robots page for detailed performance comparisons.
Head-to-Head Comparison
AbbVie and Amgen both generate substantial revenue from biologics in immunology and oncology, yet differ in scale and emphasis. ABBV maintains a larger market capitalization and broader neuroscience exposure, supported by recent acquisition activity that extends its late-stage pipeline. AMGN demonstrates strength in biosimilars and cardiovascular assets, though recent external trial news introduced short-term uncertainty. Momentum metrics favor ABBV in recent weeks due to consistent gains and positive catalysts, while AMGN trades at a comparatively lower forward valuation. Risk factors include patent expirations and regulatory scrutiny for both, with ABBV showing lower beta and AMGN facing greater near-term price swings. Sector sentiment remains constructive for established biopharma names, though relative positioning hinges on execution of ongoing clinical programs.
Tickeron AI Verdict
Based on observable factors such as trend consistency, recent pipeline developments, and relative stability, Tickeron’s AI models would currently assign a higher probability of favorable positioning to ABBV over AMGN. ABBV’s combination of positive clinical readouts and measured guidance adjustments supports more sustained momentum signals, whereas AMGN’s recent volatility tied to sector-wide developments introduces greater short-term uncertainty. This assessment reflects probabilistic evaluation of historical patterns and current data rather than definitive forecasts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and AMGN is a Buy.
| ABBV | AMGN | ABBV / AMGN | |
| Capitalization | 466B | 208B | 224% |
| EBITDA | 19.5B | 17.6B | 111% |
| Gain YTD | 18.488 | 22.576 | 82% |
| P/E Ratio | 74.56 | 23.95 | 311% |
| Revenue | 64.4B | 38.1B | 169% |
| Total Cash | 6.57B | 14B | 47% |
| Total Debt | 70.8B | 57.3B | 124% |
ABBV | AMGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 79 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 16 Undervalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 4 | 11 | |
SMR RATING 1..100 | 1 | 15 | |
PRICE GROWTH RATING 1..100 | 41 | 46 | |
P/E GROWTH RATING 1..100 | 78 | 32 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (6) in the Biotechnology industry is in the same range as ABBV (16) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to ABBV’s over the last 12 months.
ABBV's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is in the same range as AMGN (11) in the Biotechnology industry. This means that ABBV’s stock grew similarly to AMGN’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as AMGN (15) in the Biotechnology industry. This means that ABBV’s stock grew similarly to AMGN’s over the last 12 months.
ABBV's Price Growth Rating (41) in the Pharmaceuticals Major industry is in the same range as AMGN (46) in the Biotechnology industry. This means that ABBV’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's P/E Growth Rating (32) in the Biotechnology industry is somewhat better than the same rating for ABBV (78) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than ABBV’s over the last 12 months.
| ABBV | AMGN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 44% | 2 days ago 61% |
| Stochastic ODDS (%) | 2 days ago 47% | 2 days ago 57% |
| Momentum ODDS (%) | 2 days ago 65% | 2 days ago 43% |
| MACD ODDS (%) | 2 days ago 61% | 2 days ago 38% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 63% |
| TrendMonth ODDS (%) | 2 days ago 55% | 2 days ago 47% |
| Advances ODDS (%) | 8 days ago 61% | 2 days ago 62% |
| Declines ODDS (%) | 15 days ago 46% | 12 days ago 47% |
| BollingerBands ODDS (%) | 2 days ago 54% | 2 days ago 67% |
| Aroon ODDS (%) | N/A | 2 days ago 53% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 3 FA rating(s) are green while AMGN’s FA Score has 4 green FA rating(s).
- ABBV’s FA Score: 3 green, 2 red.
- AMGN’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 5 TA indicator(s) are bullish while AMGN’s TA Score has 5 bullish TA indicator(s).
- ABBV’s TA Score: 5 bullish, 3 bearish.
- AMGN’s TA Score: 5 bullish, 5 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.04% price change this week, while AMGN (@Pharmaceuticals: Major) price change was +3.06% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.29%. For the same industry, the average monthly price growth was -4.59%, and the average quarterly price growth was +16.77%.
Reported Earning Dates
ABBV is expected to report earnings on Oct 23, 2026.
AMGN is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+3.29% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with BMY. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.20% | ||
| BMY - ABBV | 51% Loosely correlated | -0.70% | ||
| NVS - ABBV | 50% Loosely correlated | +0.43% | ||
| JNJ - ABBV | 49% Loosely correlated | -0.19% | ||
| MRK - ABBV | 46% Loosely correlated | +1.79% | ||
| AMGN - ABBV | 46% Loosely correlated | +1.95% | ||
More | ||||